Yongsheng Wang

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia

Zhimin Shao, Da Pang, Hongjian Yang et al. · JAMA Oncology · 2019 · 193 citations · Full text

Medicine, Oncology, Pharmacology +17

Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial

Binghe Xu, Qingyuan Zhang, Pin Zhang et al. · Nature Medicine · 2021 · 169 citations

Medicine, Oncology, Pharmacology +12

Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial

Zefei Jiang, Quchang Ouyang, Tao Sun et al. · Nature Medicine · 2024 · 112 citations

Medicine, Oncology, Pharmacology +14

Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer

Mingxin Wen, Yong-Won Kwon, Yongsheng Wang et al. · Oncotarget · 2015 · 97 citations · Full text

Medicine, Biochemistry, Molecular Biology +10